RPG Life Sciences Q1 FY2026 net profit rises 17% to ₹30.76 crore as domestic formulations and API expand
AI Market Summary
RPG Life Sciences reported strong FY27 Q1 results, with net profit up 17% YoY, revenue up 16%, and EBITDA up 22%, supported by domestic formulations outperformance and a rebound in the API business. Margins improved modestly, indicating operating discipline despite a challenging external environment. The stock closed down 0.77%, suggesting the positive fundamentals were largely anticipated or offset by broader market positioning.
Impact level
● Low
Affected assets
NCCOGOLD2USD/USDT-1.41%
AI Insight · NCCOGOLD2USD/USDTAI Insight
● Neutral
Trade now
⚠️ AI-generated insights are based on news content and are provided for informational purposes only. They do not constitute investment advice or represent the views of BingX. Investing involves risk. Please trade responsibly.
RPG Life Sciences reported Q1 FY2026 results for the quarter ended June 30, 2026, with consolidated net profit rising 17% year on year to ₹30.76 crore. Operating revenue increased 16% to ₹195.69 crore. EBITDA climbed 22% to ₹43.29 crore and the EBITDA margin improved to 22.1%. The company attributed the performance to strong growth in domestic formulations and its active pharmaceutical ingredients (API) business.
